Hepatorenal Syndrome Treatment Mark CAGR Status, Growth Opportunities and Analysis on Forecast 2029.

Hepatorenal Syndrome Treatment Market is expected to reach US$ 13.73 Bn. at a CAGR of 13.12% during the forecast period 2029. Hepatorenal syndrome (HRS) is a life-threatening medical disorder in which kidney function rapidly deteriorates in those who have cirrhosis or fulminant liver failure. Unless a liver transplant is performed, HRS is usually deadly, while other therapies, such as dialysis, might slow the progression of the disease.